![black female scientist fills vials](/sites/default/files/styles/445x610/public/media/images/black_female_scientist_fills_vials.jpg.webp?itok=TzBxb-qF)
Biomarker types and colorectal cancer
![black female scientist fills vials](/sites/default/files/styles/445x610/public/media/images/black_female_scientist_fills_vials.jpg.webp?itok=TzBxb-qF)
Biomarkers 101
Learn the basics about biomarkers and colorectal cancer, why testing is important, and what learning about your biomarker mutations can mean for your treatment options and cancer outcomes.
![black couple with their infant](/sites/default/files/styles/1600x600/public/media/images/black_family_3.jpeg.webp?itok=GDJxpBnH)
Biomarker type resource guide
This resource grid details the different types of biomarkers and how they relate to a colorectal cancer diagnosis and treatment.
![young Latin woman smiling in hospital bed](/sites/default/files/styles/fifty_fifty/public/media/images/woman_hospital_bed_thumbs_up_0.jpeg.webp?itok=rDsiOp83)
The Alliance’s personalized treatment program
The Alliance and Perthera have partnered to provide personalized treatment options to stage III and IV patients with colorectal cancer.
If you recently had molecular/biomarker testing, your results will be analyzed with no additional testing required.
Call us at the Alliance’s Helpline at (877) 422-2030 to enroll.
Related reading
SidednessTop resources
![A sign at the BMS headquarters](/sites/default/files/styles/450x250/public/media/images/bms-sign-1920.png.webp?itok=qtRzhXHJ)
Krazati approved for previously treated KRASG12C colorectal cancer
The treatment option is for patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC) who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
![The city of Philadelphia](/sites/default/files/styles/450x250/public/media/images/philadelphia.png.webp?itok=CyT8nkqx)
Alliance adds partners to expand 45+ Reasons campaign
The Alliance’s 45+ Reasons campaign is part of the Cycles of Impact initiative launched and supported by Independence Blue Cross in 2022 to address the urgent public health issue of colorectal cancer among the Black population.
![Pillars in front of a court building](/sites/default/files/styles/450x250/public/media/images/court-pillars_0.png.webp?itok=vjw6DOGa)
Appeals Court decision protects access to no-cost preventive CRC screening
The U.S. Court of Appeals for the Fifth Circuit reversed a district court decision that had ruled provisions in the Affordable Care Act (ACA), which provide for no-cost preventive screening for colorectal cancer and other conditions, unconstitutional.